Literature DB >> 24978384

Rituximab in pure red-cell aplasia secondary to anti-erythropoietin antibodies.

Thibault Comont1, Barbara Bournet2, Nicole Casadevall3, Dominique Chauveau4, Stanislas Faguer4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24978384     DOI： 10.1038/ki.2014.144

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  1 in total

1.  Rituximab: A viable treatment option for epoetin-induced pure red cell aplasia.

Authors:  S A Mahajan; N Nandagopal; M Soni; R A Annigeri
Journal:  Indian J Nephrol       Date:  2015 Nov-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.